Share Name Share Symbol Market Type Share ISIN Share Description
Sensyne Health Plc LSE:SENS London Ordinary Share GB00BYV3J755 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -0.98% 101.50 118,260 08:10:57
Bid Price Offer Price High Price Low Price Open Price
100.00 103.00 102.50 101.50 102.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 131
Last Trade Time Trade Type Trade Size Trade Price Currency
10:56:56 O 115,368 102.00 GBX

Sensyne Health (SENS) Latest News

More Sensyne Health News
Sensyne Health Takeover Rumours

Sensyne Health (SENS) Share Charts

1 Year Sensyne Health Chart

1 Year Sensyne Health Chart

1 Month Sensyne Health Chart

1 Month Sensyne Health Chart

Intraday Sensyne Health Chart

Intraday Sensyne Health Chart

Sensyne Health (SENS) Discussions and Chat

Sensyne Health Forums and Chat

Date Time Title Posts
20/11/201921:55Sensyne Health PLC78
20/11/201921:54Sensyne Health - Clinical AI1

Add a New Thread

Sensyne Health (SENS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sensyne Health trades in real-time

Sensyne Health (SENS) Top Chat Posts

Sensyne Health Daily Update: Sensyne Health Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SENS. The last closing price for Sensyne Health was 102.50p.
Sensyne Health Plc has a 4 week average price of 97.50p and a 12 week average price of 97.50p.
The 1 year high share price is 190p while the 1 year low share price is currently 97.50p.
There are currently 128,571,514 shares in issue and the average daily traded volume is 37,985 shares. The market capitalisation of Sensyne Health Plc is £130,500,086.71.
rambutan2: As requested, a new thread for an interesting company with a rather depressed share price.
zulu_principle: Small snippet of news – Sensyne has been named “European Healthtech Company of the Year” at last night’s European Lifestars Awards. “The award recognises a European Healthtech (digital health, digital therapeutics, databases, applications and wearables) company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for consumer, patients, investors, employees and the broader life science community.“ There seems to be a substantial stock overhang to clear before the share price recovers. Small sells result in almost immediate price drops whereas a succession of moderate buys make almost no impact. Woodford’s remaining 10.2% disappeared a couple weeks back from the list of major shareholders and doesn’t seem to have been fully picked up by existing investors or by a new entrant. Any views out there?
rambutan2: Plenty to be excited about, albeit you have to remember that SENS is a young company and the model is just getting going/being proven. The Bayer agreement was significant and should lead to more such deals, in time. No doubt there will be hiccups along the way, but it's got enough cash (currently £41.5m) for a couple of years yet, so has breathing space. Woodford's 12% is clearly depressing the share price at present but I can't believe that this won't bounce big before long. htTps://
ayl30: So in light of share price decline what do people make of today's results?
the stigologist: The recent listings of Sensyne (SENS) (formerly known as Drayson Health) and Renalytix (RENX) have focused attention of UK investors on the new AI MedTech sector. Companies such as this in the AI/Machine Learning MedTech space "use anonymised data from the NHS to diagnose patterns in cancer and other diseases ...then pass on findings to drug companies so they can develop treatments faster and more cost-effectively than in the past." The rich valuations enjoyed by SENS and RENX have caused investors to look for other companies in the sector which may be 'hidden gems'. One such is Physiomics (PYC). Whilst Sensyne and Renalytix are valued at £240m and £70m despite have zero in revenues Physiomics is valued at only £3m AND has revenues of c. £0.5m However when considering how to value Physiomics it's important to realise there are two major strands to it's business. One strand is its 'legacy' Modelling and Simulation business which last year signed a E0.5m deal with Merck KgGA. This part of the business is analagous to the likes of Simulations Plus a $400m Mkt Cap Nasdaq listed comparitor with c.$20m in revenues. Thus one could apply a 'rating' of 10-20x revenues to value Physiomics business in this area. (£0.4m x 10-20x = £4.0-8.0m) The new strand to Physiomics business is it's AI/Personalised Medicine business. In this part of the business Physiomics has won research grant funding from the UK Government's InnovateUK to progress several studies on specific cancers in association with Oxford University academics and Oxford NHS. e.g. Oesophagal Cancer study hTtps:// Prostate Cancer study hTtps:// This part of Physiomics business is similar to and should be valued with reference to its newly listed comparitors Renalytix (RENX) and Sensyne (SENS). Those valuations would suggest a very wide potential range from £70m to £240m. Putting together the 'sum of the parts' we can conclude that a case can be made for valuing Physiomics currently as 'worth' somewhere within a range of £74-248m. In terms of share price with 72m shares in issue this would imply a potential valuation range of c.100-350p Clearly at a mere 5p the market has a lot of catching up to do in valuing Physiomics correctly.
Sensyne Health share price data is direct from the London Stock Exchange
Your Recent History
Sensyne He..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191121 14:10:06